Novo publishes an indirect comparison favoring the Wegovy pill over orforglipron

Novo Nordisk announced a new cross-trial analysis on April 2, 2026, comparing its oral semaglutide 25 mg (Wegovy pill) against orforglipron, the competing GLP-1 pill sold as Foundayo, which had just won FDA approval one day earlier ^[1]. The analysis reported greater average weight loss with the Wegovy pill and lower odds of patients stopping treatment because of gastrointestinal side effects ^[1].

The comparison is titled "Wegovy Pill Demonstrated Greater Weight Loss Than Orforglipron and Lower Odds of Stopping Medication Due to Side Effects," and Novo Nordisk says it will present the findings at the Obesity Medicine Association 2026 meeting ^[1]. Wegovy's oral tablet form was approved by the FDA on December 22, 2025, as the first and only oral GLP-1 medicine for weight loss in adults, available in 1.5 mg, 4 mg, 9 mg, and 25 mg tablet strengths taken once daily on an empty stomach ^[1]. That approval, and the drug's broader label for weight management and cardiovascular risk reduction, forms the backdrop against which Novo Nordisk is now positioning its pill against orforglipron ^[1].

A key detail readers should understand is what kind of study this is. It is not a randomized head-to-head trial where patients were assigned to take one drug or the other. Instead, it is a population-adjusted indirect comparison, a statistical method that combines and adjusts data from separate trials — in this case pulling from the oral semaglutide program and the orforglipron trial program — to estimate how the two drugs might compare if they had been tested against each other directly ^[1]. This kind of analysis can be useful for spotting patterns, but it carries more uncertainty than a real head-to-head study, and it was funded and conducted by Novo Nordisk, the company that makes the drug reported to perform better ^[1].

Why it matters for patients

For people choosing between an oral semaglutide product like the Wegovy pill and orforglipron (Foundayo), this analysis adds a new data point, but it should be read with caution. The company that stands to benefit from favorable results produced the comparison, and it used indirect statistical methods rather than a trial where patients actually took both drugs under the same conditions ^[1]. That does not mean the findings are wrong, but it does mean they are not as strong as evidence from a true head-to-head trial would be.

Patients and their doctors weighing these two oral options may want to consider gastrointestinal tolerability alongside weight-loss results, since both were highlighted in Novo Nordisk's analysis ^[1]. Common side effects reported for the Wegovy injection and tablet forms include nausea, diarrhea, vomiting, constipation, abdominal pain, and related digestive symptoms, which are consistent with the kind of gastrointestinal effects that lead some patients to stop GLP-1 medicines altogether ^[1]. How orforglipron's tolerability compares in real-world use, outside of Novo Nordisk's adjusted analysis, is not yet established in the sources reviewed here.

What happens next

Novo Nordisk says it plans to formally present the comparison data at the Obesity Medicine Association's 2026 meeting, where independent researchers and clinicians will have a chance to review and question the methodology ^[1]. Until an actual randomized head-to-head trial between the Wegovy pill and orforglipron is conducted, if one is, patients and doctors will be relying on indirect comparisons like this one, along with each drug's separate trial results, to make treatment decisions. No date for such a head-to-head study appears in the available sources.